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Abstract
Background: The aim of this study was to analyse breast cancer incidence and mortality in Tyrol from 1970 to
2006, namely after performing more than a decade of opportunistic mammography screening and just before
piloting an organised screening programme. Our investigation was conducted on a population level.
Methods: To study time trends in breast cancer incidence and mortality, we applied the age-period-cohort model
by Poisson regression to the official mortality data covering more than three decades from 1970 to 2006 and to
the incidence data ranging from 1988 to 2006. In addition, for incidence data we analysed data on breast cancer
staging and compared these with EU guidelines.
Results: For the analysis of time trend in breast cancer mortality in age groups 40-79, an age-period-cohort model
fits well and shows for years 2002-2006 a statistically significant reduction of 26% (95% CI 13%-36%) in breast
cancer mortality as compared to 1992-1996.
We see only slight non-significant increases in breast cancer incidence. For the past five years, incidence data show
a 10% proportion of in situ cases, and of 50% for cases in stages II+.
Conclusions: The opportunistic breast cancer screening programme in Tyrol has only in part exploited the
mortality reduction known for organised screening programmes. There seems to be potential for further
improvement, and we recommend that an organised screening programme and a detailed screening database be
introduced to collect all information needed to analyse the quality indicators suggested by the EU guidelines.
Background
Breast cancer (BC) is the leading cause of female cancer
death in all industrialised countries (and also worldwide)
and the breast is also the leading incident cancer site for
females [1]. Therefore, screening methods for BC are of
greatest public health importance. Efficiency and efficacy
of organised mammography screening programmes have
been proven in large randomised trials conducted in
Europe and North America. For several years already,
organised mammography screening programmes have
been recommended in the EU[2]. Austria is one of the
European countries where up to 2006 no organised
programmes were implemented, but where coverage in
spontaneous mammography screening could have been
rather high. In a micro-census conducted in Austria in
2006-2007, more than 80% of women aged 40-59
answered that they had had at least one mammography
(ever) and more than 40% had had one in the past year
[3]. However, it is known that self-reporting of screening
usage overestimates true coverage [4], and first prelimin-
ary data from the organised mammography screening
programme in Tyrol strongly confirm this interpreta-
tion. In 2006, the Austrian health minister declared
mammography to be one of the top health agendas, and
in July 2006 a decision was made to implement orga-
nised mammography screening programmes, in a first
step in pilot regions, of which Tyrol is the largest. * Correspondence: willi.oberaigner@iet.at
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s e tu pa r o u n d1 9 9 3 .I nJ u l y1 9 9 8t h e“Working Group
for Early Breast Cancer Detection for Tyrol” was estab-
lished. Since that year recommendations including
monthly breast self-examination, annual examination by
a physician and annual mammography, if necessary with
adjunctive breast sonogram, beginning at age 35-40,
were formulated. Assessment is offered centrally by
eight hospitals. Results of this strategy have been pub-
lished [5]. Generally, in Austria spontaneous mammo-
graphy screening is offered in the framework of general
health exams done by general practitioners and of
gynaecologic exams performed by gynaecologists in pri-
vate practice. Women are referred for screening mam-
mography mostly to radiologists in private practice.
Both services are free of charge for women as of age 40.
In 2007 and 2008, five pilot projects were launched in
several of Austria’s federal states in order to evaluate
how to implement organised mammography screening.
In Tyrol, a state screening programme was started in
June 2007. In a one-year pilot phase, the methods were
tested in two counties of Tyrol and in June 2008 the
programme was extended to the whole state of Tyrol.
The basic goal was to smoothly change the existing
opportunistic screening system. Main characteristics are
personal invitation, screening offered by radiologists and
hospitals (out-patient departments), assessment at two
hospitals, training of all partners and careful quality
control by collecting all data in a central screening data-
base and periodic inspection of data by a medical quality
assurance group. No double reading was implemented.
We feel there is a need to publish the baseline charac-
teristics of incidence and mortality in order to give a
transparent public view of the situation in Tyrol before
changing the mammography system. Although pro-
gramme characteristics have not been collected to date,
we can roughly judge the outcome achieved with the
former spontaneous system by analysing time trends in
incidence and mortality and by looking at stage shifts in
BC cases. To our knowledge, it is not only in our coun-
try that spontaneous mammography screening is offered
to women broadly, and there is ongoing discussion
about whether the mammography system should be
changed [6]. Therefore, it is of general interest to ana-
lyse the effects of spontaneous mammography screening
offered free of charge to all women in a population. The
analysis was only to be published now, because mortality
and incidence data for female BC in Tyrol were pub-
lished just a few months ago for the period to 2006 [7].
It was our aim to analyse BC incidence and mortality
before changing the mammography system in Tyrol and
to estimate the effects of the spontaneous programme
offered free of charge to women for about fifteen years
in order to have a public discussion of results before
making the decision on whether and how to change the
mammography system in Tyrol.
Methods
Mortality Data
M o r t a l i t yd a t aa r ec o l l e c t e db yS t a t i s t i c sA u s t r i af o rt h e
whole of Austria [8]. In Austria, death certificates are
issued by official, specially trained medical doctors,
pathologists and forensic medical experts. Specialists at
Statistics Austria, the federal institution for statistics in
Austria, follow international guidelines and select one
main diagnosis that led to death and assign it one ICD
code (ICD9 up to 2001, ICD10 since 2002). All proce-
dures concerning death certificates, data collection and
coding are applied in a uniform way throughout Austria
and are not state-specific. We analysed all female cases
coded for cause of death BC as described above.
Incidence Data
Incidence data have been collected by the Cancer Regis-
try of Tyrol since year of diagnosis 1988 on a popula-
tion-based perspective. Publication of incidence data in
Cancer Incidence in Five Continents gives some hints
for good completeness and validity of the database
[9,10]. Registration is performed from a standardised
questionnaire including sex, age, cancer site and histol-
ogy, date of diagnosis, stage and basic information on
primary treatment. Information on co-morbidity is not
collected routinely. There are strict rules for collecting
these variables in accordance with international
guidelines. Either the questionnaire is completed by a
physician or a Cancer Registry clerk collects data
directly from clinical records in the treating hospital.
Modelling of time trends
Time trends were analysed by fitting age-period-cohort
(APC) models [11,12]. APC models allow separate
effects to be estimated for age (A), period or year of
death (P) and cohort (C) by means of Poisson regres-
sion. In a more formal sense we fit a series of models
log( )    APC A P C 
where C=P-A, and r, denotes the mortality rate
The model is often written in antilogs as follows:
   APC A P C   
where aA’ denotes the antilog of aA or aA’ =e x p ( aA)
etc.
As suggested by Clayton and Schifflers, a series of
models is fit until adequate model fit is attained. We
start with A alone and proceed by including P and/or C
in the model if model fit is not sufficient without the
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improves goodness of fit. Goodness of fit is measured by
deviance, which should be equal or close to the degrees
of freedom (DF) if model fit is reasonably good.
For statistical analysis the number of BC deaths was
aggregated in ten-year age groups and five-year period
groups. We started with age group 40-49 and continued
in ten-year age groups ending with age group 70-79,
because we expected mammography screening to also
affect this age group, bearing in mind that women aged
60-69 at the beginning of the screening programme
around 1993 are now in age group 70-79. We have
access to mortality data beginning in 1970. Our first
period group was 1972-1976 in order to finish with the
five year group 2002-2006. Our hypothesis was that the
mortality rate decreased following the introduction of
mammography screening around 1993. Thus, the refer-
ence category was the period 1992-1996. Consequently,
because C = P-A, cohort groups begin with a cohort
group centred at 1899.
To analyse the incidence time trend, we fitted an APC
model for age groups 40 to 69, namely the age groups
aimed at by the screening programme. The incidence
data set begins with 1988. Therefore, we defined period
groups 1988-1991 and then five-year period groups end-
ing with 2002-2006.
For incidence data, we also analysed the proportion of
in situ cases and the proportion of stages according to
UICC and compared these with accepted levels given by
EU guidelines [2].
Age-specific rates were calculated using official popu-
lation numbers as denominators. Population data are
also collected by Statistics Austria. Census data are
available for the years 1971, 1981, 1991 and 2001; for
intercensus years population figures are extrapolated
based on birth, death and migration information. The
female population of Tyrol in the census year 2001 was
345,757. The analysis was performed with Stata, Version
9; the APC model was set up using the procedure pois-
son for Poisson regression [13].
This study was conducted in conformity to the Hel-
sinki Declaration [14].
Results
For an impression of overall BC mortality and incidence,
Figure 1 shows the time trend in age-standardised mor-
tality and incidence rates (for all age groups); age stan-
dardisation was based on world population proposed by
SEGI and modified by Doll et al. [9]. The line of moving
averages suggests a decline in mortality since 1998 and
an increase in incidence until 2003, however on a purely
descriptive level.
For a formal analysis of time trend, we fitted an APC
model separately for mortality and incidence. For
mortality, the final model includes terms for period and
cohort because there are statistically significant cohort
effects, model fit is very good (8 degrees of freedom,
deviance 3.5). The resulting estimates for the APC
model are described in Table 1 and Figure 2. Age
effects, each compared to age group 40-49, are 2.15 for
age group 50-59, 3.67 for age group 60-69 and 5.75 for
age group 70-79. Period effects, each compared to 1992-
1996, are about 1.05 before 1992, but 0.83 (95% CI 0.57,
1.21) for 1997-2001 and 0.74 (95% CI 0.64, 0.87) for
2002-2006. In general, the effects we report can be
interpreted a change in mortality compared to the refer-
ence period, for example the effect of 0.83 for year
1997-2001 means a mortality reduction of 17% in 1997-
2001 as compared to 1992-96. We also observe a strong
cohort effect for cohorts born around 1920 and between
1930 and 1950 with relative risks at 1.4-1.8, each com-
pared to the cohort centred at 1899.
For incidence, the time period from 1988 to 2006 is
much shorter. We modelled the time trend for age
groups for which mammography screening was recom-
mended, namely 40 to 69. The AP model reaches suffi-
cient model fit with 8 degrees of freedom and a
deviance of 8.3. Since adding a cohort parameter does
not cause a significant improvement, we accepted the
AP model. Period effects, each compared to 1992-1996,
show a non-significant increase in BC incidence up to
1992, a slight but non-significant increase of 1.05 after
1996 and a steady situation during the last five years,
see Table 2.
In addition, we also analysed some of the quality indi-
cators proposed by EU guidelines [2]. The proportion of
in situ cancers out of the total in situ and invasive can-
cers shows a steady increase from 5% around 1990 to
13% around 2000 and a slight decrease to 10% in recent
years (see Figure 3). This time trend is consistent for all
three age decades investigated (data not shown) and
meets the 10% acceptable level given by EU guidelines.
Figure 3 shows staging groups according to UICC. We
see a clear stage shift towards early stages I and II up to
around 2000 and a slight decrease afterwards. The EU
acceptable proportion of stages II+ (30%) is clearly
missed; in the last years the proportion of stages II+ in
Tyrol was about 50%.
A more detailed analysis for the last five years shows a
proportion of very small cancer with a size of less than
1 cm (TNM staging T1a,b) of 24% (age group 40-49),
22% (age group 50-59) and 19% (age group 60-69), the
acceptable level according to EU guidelines being 25%.
However, this information is not available for the 1990s.
The proportion of node-negative cases also increased
to 58% (age group 40-49) and 53% (age group 50-69) at
about 2000, the acceptable proportion in EU guidelines
being 70%.
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vant hormonal therapy resulted in a hazard ratio of 0.87
(95% CI 0.77, 0.99) adjusted for age and stage, this
means that patients receiving adjuvant hormonal ther-
apy have a 13% lower risk of death than patients with-
out this therapy.
Discussion
Our results indicate a significant decrease in BC mortality
over the past five years, a nonsignificant slight increase in
incidence and a stage shift towards early stages over the
past fifteen years with some proportions in the range of
the accepted levels given by EU guidelines.
Strengths and Limitations
This observational study was conducted in the popula-
t i o no fT y r o l .M o r t a l i t ya n di n c i d e n c ed a t aw e r ec o l -
lected on a population level. Mortality data were
provided by Statistics Austria. The quality of death certi-
ficates was very important for the conclusions drawn. In
general, mortality statistics in Austria have been of high
quality for decades [8]. Coding of cause of death is done
according to international guidelines by specialists who
attend international benchmarking exercises. As already
stated above, death certificates are written by specially
trained doctors.
Data on BC incidence on a population level are pro-
vided by the Cancer Registry of Tyrol, which is a mem-
ber of IACR and whose data are published in Cancer
Incidence in Five Continents, thus giving some evidence
for good quality of incidence data [9,10,15]. Figures on
completeness of incidence data show that for BC, in the
past decade the proportion of death certificate-notified
cases was 3.2% and the proportion of death certificate
only cases 1.4% [7]. Both proportions allow the conclu-
sion that completeness is good as compared to interna-
tional data.
In addition, the proportion of cases with unknown or
unspecified stage is less than 5% in age groups 40 to 69.
When we analyse incidence data on a population level,
we always encounter some cases that lack detailed infor-
mation for various reasons. Since year of diagnosis 2004,
the cancer registry includes a variable for mode of
detection. However, the information is very incomplete,
because in many cases we cannot obtain sufficient infor-
mation from the hospital discharge records.
The model we fitted for analysis of the time trend
shows very good model fit. This means we can trust the
time trend parameters and can therefore draw reliable
conclusions from the model. Moreover, the staging
information used to describe stage shift should be
reliable.
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Page 4 of 9The main limitation is the lack of a screening data-
base. Consequently, we do not have detailed information
on screening performance parameters. Another weak-
ness is that we have only some limited information on
coverage from a micro-census performed in 2006/2007
and from a publication by Frede [5]. Both sources indi-
cate a coverage of 70%. In Catalonia, Spain, Baré et al
[16] reported also a coverage of 70% prior to introdu-
cing a screening programme and the authors investi-
gated reasons for non-participation which can be very
helpful in improving coverage. On the other side, it is
known that self-reporting overestimates true coverage,
[4] and a more realistic estimation could be a coverage
of about 50%. This would fit to first preliminary data
from the organised programme in Tyrol (data not
shown). The lack of information on coverage and, of
course, also on many other screening details was one of
the reasons for changing the screening system, because
we are convinced that a detailed knowledge of screening
parameters is essential to draw valid conclusions in
future. For staging distribution, the only source of infor-
mation is the Cancer Registry dataset, whose focus was
not to obtain information on screening indices but to
concentrate on cancer cases.
Time trend for mortality and incidence data, model fit
We applied an APC model that takes age, period and
cohort effects into account and models time trends that
differ from a linear trend. Such models are widely used
in epidemiology, see for example [17,18]. Each of the
models we applied for both mortality and incidence fits
well on its own, and all parameters allowing judgment
of model fit are reasonably good. Also, the graphs show-
ing observed and predicted rates give additional evi-
dence that the model describes the data very well and
hence that we can rely on estimated parameters (graphs
not shown). In summary, the time trends given by the
models should adequately describe the situation we
observe.
Concerning the decrease in BC incidence in recent
years, Ravdin et al. [19] hypothesized for the USA that
the reduction in hormone replacement therapy (HRT) is
the main cause of the rapid decrease in BC incidence
seen in the USA from 2003 to 2004. Also in Tyrol, we
o b s e r v ead e c r e a s ei nB Ci n c i d e n c eo n l yi na g eg r o u p s
50+, although the decrease is not as sharp as in the
USA. According to local experts, it is likely that also in
Tyrol, part of the decrease in breast cancer incidence in
the age group 50+ between 2004 and 2006 is due to a
reduction in HRT.
The main question remains whether the significant
26% reduction in BC mortality over the past five years
as compared to 1992-1996 is associated with opportu-
nistic mammography screening. Both randomised trials
a n dd a t af r o mp o p u l a t i o n - b a s e do r g a n i s e dm a m m o g r a -
phy screening programmes provide clear evidence that
organised mammography screening can reduce BC mor-
tality. This was also communicated at an IARC interna-
tional expert conference [20]. The extent of mortality
reduction differs in detail, but in general is estimated to
be between 20% and 25% [21-32]. However, for popula-
tion-based organised programmes it is necessary to dis-
tinguish between various factors influencing BC
mortality [33]. Some authors[33] estimate that a great
part of BC mortality reduction (approximately 2/3 of
reduction in England and Wales) is related to improve-
ments in therapy, mainly the introduction of tamoxifen.
For the USA, Berry et al. [34] found a range of 28% to
65% (median 46%) for the proportion of BC mortality
reduction attributed to screening by modelling this pro-
portion by seven independent investigators. For Tyrol,
this would imply a mortality reduction of 7% to 17%
attributable to screening. In addition, when comparing
BC mortality trends between countries, stage
Table 1 Model estimators for age, period and cohort
given by the APC model, drift in period, for breast
cancer mortality in Tyrol 1972-2006
Estimator 95% CI
Age
40-49 1 Reference
50-59 2.15 1.85 2.50
60-69 3.67 3.05 4.42
70-79 5.75 4.58 7.22
Period
1972-1976 1.12 0.92 1.37
1977-1981 1.07 0.79 1.44
1982-1986 1.07 0.91 1.26
1987-1991 1.05 0.74 1.48
1992-1996 1 Reference
1997-2001 0.83 0.57 1.21
2002-2006 0.74 0.64 0.87
Cohort (centred at)
1899 1 reference
1904 Collinearity
1909 1.06 0.84 1.35
1914 1.20 0.92 1.56
1919 1.41 1.11 1.77
1924 1.32 0.98 1.77
1929 1.27 0.99 1.62
1934 1.60 1.13 2.28
1939 1.61 1.21 2.15
1944 1.80 1.18 2.74
1949 1.48 1.04 2.09
1954 1.55 0.90 2.66
1959 Drift
* Because there is drift in period, there is no estimator for the last cohort
centered at 1959
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Page 5 of 9distribution and differences in therapy also have to be
discussed as factors influencing BC mortality at the
population level.
Adjuvant therapy with tamoxifen was routinely intro-
duced in Tyrol around 1985. We do not collect detailed
information on BC therapy in the Cancer Registry, but
we have an overall variable for adjuvant hormonal ther-
apy. When we analysed the effect of adjuvant hormonal
therapy in a COX model adjusted for age and stage, an
overall effect of 13% was seen. With regard to time
trend in survival rates, over the past fifteen years we
observed an increase in relative five-year survival rates
split by staging groups according to UICC (5% increase
in stage I, 13% in stage II, and 5% in stage IV). Both
observations are consistent with an estimated therapy
effect on survival of between 10% and 15%, which is in
line with the UK estimate [21]. Furthermore, as com-
pared with EU guidelines, we miss some of the accepted
levels (coverage, proportion of small cancers, proportion
of II+ cancers, proportion of node-negative cancers). In
conclusion, we estimate that less than half of the mor-
tality reduction should be due to screening. This would
mean that the screening effect is less than 13% and that,
consequently, the opportunistic screening programme
does not realise the potential of organised programmes,
namely a mortality reduction of 20% - 25%.
However, when we compare BC data for Tyrol with
quality indicators for mammography screening, we must
remember that the BC data we analysed included all BC
cases diagnosed in the population of Tyrol, not only
those detected by opportunistic mammography screen-
ing. For example, Paci et al. [35] show a proportion of
53% for II+ breast cancer in the total population as
opposed to 29% in the screen-detected subgroup.
Vutuc et al. recently analysed BC mortality in Austria
[6]. The authors argue that BC screening is a plausible
explanation for BC mortality reduction and doubt that a
change in screening policy (meaning changing from
opportunistic screening to an organised programme)
would significantly improve the situation in Austria. We
agree that BC screening is indeed one possible explana-
tion for BC mortality reduction. However, if we take
into consideration the fact that we have no detailed
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Figure 2 Breast cancer mortality, APC model, P estimators; age groups 40-79.
Table 2 Model estimators for age and period given by
the AP model, for breast cancer incidence in Tyrol 1988-
2006
Estimator 95% CI
Age
40-49 1 Reference
50-59 1.65 1.53 1.79
60-69 2.08 1.93 2.25
Period
1988-1991 0.92 0.83 1.01
1992-1996 1 Reference
1997-2001 1.05 0.96 1.14
2002-2006 1.05 0.96 1.14
Remark: There is no significant cohort effect. Therefore, the model was set up
without cohort terms.
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Page 6 of 9information on diagnostic performance or coverage for
opportunistic BC screening in Austria, we feel it is abso-
lutely necessary that detailed information on mammo-
graphy screening be collected, at least for several years.
We need to know all the well-established quality indices
for BC screening[2] before we can draw a final conclu-
sion on how to proceed with mammography screening
in Austria.
Interestingly, the greatest reduction in BC mortality
was observed in the age group 40 to 49. This differs
somewhat from international data, where doubts still
prevail on the efficacy of mammography screening in
the age groups below 50, see for example [36,37]. Surro-
gate performance indicators like stage shift, cancer size
less than 1 cm and proportion of node-negative cancer
also showed a clear tendency towards better perfor-
mance in the age group 40 to 49 as compared to the
a g eg r o u p s5 0t o5 9a n d6 0t o6 9 .I na d d i t i o n ,d u r i n g
the past decade, these indicators improved more quickly
in the age group 40 to 49 (details not shown). One pos-
sible explanation is the wide-spread use of sonography
as an adjunct to mammography in Tyrol. It has been
shown by various authors that the additional use of
sonography can improve cancer detection rates, espe-
cially in younger women and women with dense breasts.
The relative percentage of carcinomas found in supple-
mental breast ultrasound examinations as a fraction of
the total number of detected cancers was reported by
four studies, with a mean percentage of 22.5% (15%-
34%) [38].
In opportunistic screening in Tyrol, sonography was
offered to women with dense breasts (ACR density
grades 3 and 4) and with inconclusive findings on mam-
mography [39]. In addition, women in the younger age
groups are likely to go more frequently to their general
practitioner or gynaecologist, which results in higher
coverage by opportunistic screening [3].
The discussion in the USA after publishing the revised
recommendation by U.S. Preventive Services Task Force
[40,41] shows that it is very challenging and hard to
understand by women to remove a service that was
recommended for several years. Without well founded
data, we feel it is not justified to stop screening in age
class 40-49. We are collecting detailed data and will
evaluate the balance between goods and harms during
the next years.
Some of the EU recommendations like double reading
and making an appointment for mammography when
inviting women will not be part of the organised pro-
gramme in Tyrol. Thus, further investigation will be
needed to prove whether mammography screening has
an effect on BC mortality, even in the absence of these
EU recommendations.
Conclusions
Up to now, in terms of BC mortality reduction our ana-
lysis shows that it is likely that the full potential of
mammography screening has not yet been realised. In
addition, available cancer registry data are not sufficient
to assess the efficiency or efficacy of the current
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Page 7 of 9opportunistic screening programme. Therefore, to ana-
lyse surrogate indices like decrease in advanced stages
and increase in early stages, interval cancer rates, and to
investigate the cost efficiency of the established pro-
gramme, it is absolutely necessary that a well-organised
screening database be built up that contains all informa-
tion needed to analyse the quality indicators suggested
by the EU guidelines. In conclusion, we strongly advise
that an organised mammography screening programme
be introduced in Tyrol, namely one that will also allow
a detailed analysis of the effects of mammography
screening.
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